Added to YB: 2025-02-18
Pitch date: 2025-02-15
NVO [bullish]
Novo Nordisk A/S
-37.42%
current return
Author Info
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
Market Cap
DKK 1.4T
Pitch Price
DKK 80.49
Price Target
755.63 (+1406%)
Dividend
3.63%
EV/EBITDA
8.96
P/E
13.76
EV/Sales
4.74
Sector
Pharmaceuticals
Category
value
Novo Nordisk: Time to Buy the dip?
NVO: Diabetes/obesity leader down 43% from peak. CagriSema Phase 3 missed 25% target (-22.7%). Zepbound outperforms Wegovy. Still 55% GLP-1 market share. 16-24% rev growth, 85% margins. Risks: Lilly threat, production bottlenecks, regulatory. DCF shows 28.72% upside. Buying opportunity?
Read full article (3 min)